Erasca (ERAS) Non-Current Assets (2020 - 2026)
Erasca's (ERAS) quarterly Non-Current Assets came in at $207.4 million in Q1 2026, up 32.45% YoY from $156.6 million in Q1 2025, and up 88.74% on a QoQ basis from $109.9 million in Q4 2025.
Erasca (ERAS) Non-Current Assets (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Non-Current Assets data on file, last reported at $207.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 32.45% year-over-year to $207.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $572.6 million (down 12.83% YoY) and the FY2025 annual result came in at $109.9 million, down 43.26% from the prior year.
- Non-Current Assets improved to $207.4 million in Q1 2026, from $109.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $207.4 million in Q1 2026 to a low of $63.4 million in Q1 2024.
- A 5-year average of $114.9 million and a median of $109.9 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 384.28% — and 2025, when it plunged 43.26%.
- Tracing ERAS's Non-Current Assets over 5 years: stood at $70.4 million in 2022, then advanced by 5.98% to $74.6 million in 2023, then soared by 159.62% to $193.7 million in 2024, then sank by 43.26% to $109.9 million in 2025, then jumped by 88.74% to $207.4 million in 2026.
- The last three Non-Current Assets figures came in at $207.4 million (Q1 2026), $109.9 million (Q4 2025), and $120.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 156.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 156.61 Mn |
| Mar 31, 2026 | 207.45 Mn |
| Dec 31, 2025 | 109.92 Mn |
| Sep 30, 2025 | 120.48 Mn |
| Jun 30, 2025 | 134.73 Mn |
| Mar 31, 2025 | 156.63 Mn |
| Dec 31, 2024 | 193.73 Mn |
| Sep 30, 2024 | 198.72 Mn |
| Jun 30, 2024 | 107.74 Mn |
| Mar 31, 2024 | 63.40 Mn |
| Dec 31, 2023 | 74.62 Mn |
| Sep 30, 2023 | 113.44 Mn |
| Jun 30, 2023 | 116.81 Mn |
| Mar 31, 2023 | 69.66 Mn |
| Dec 31, 2022 | 70.41 Mn |
| Sep 30, 2022 | 80.68 Mn |
| Jun 30, 2022 | 63.40 Mn |
| Mar 31, 2022 | 72.10 Mn |
| Dec 31, 2021 | 81.40 Mn |
| Sep 30, 2021 | 29.64 Mn |